A Phase II, Open-Label, Multi-Drug, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary)
RecruitingCTIS2022-502317-29-00
AstraZeneca ABAdvanced Hepatobiliary Cancer
Start: 2023-07-12Target: 60Updated: 2025-12-11